“ THE PHARMACEUTICAL INDUSTRY NEEDS A NEW AND INNOVATIVE APPROACH TO CLINICAL TRIALS ”
FIVE MINUTES WITH ...
CAROLINA ROSSI WOSIACK
MANAGING DIRECTOR FOR EMEA AT DIGITAL CONSULTANCY FIRM CI & T
Wosiack has helped transform leading pharma companies such as Roche , Sanofi and Johnson & Johnson to adapt to the digital world . Here she tells us about modernising clinical trials .
Q . WHY ARE CLINICAL TRIALS SO COMPLEX ?
» Traditional clinical trials are costly , inefficient and logistically demanding . Recruiting volunteers and patients , and then retaining them has long been a problem . With the world expected to see more infectious disease outbreaks in the future , traditional trial models and practices are no longer sustainable . The pharmaceutical industry needs a new and innovative approach to clinical trials – one that will ensure patients have access to lifesaving treatments regardless of black swan events like the global pandemic .
“ THE PHARMACEUTICAL INDUSTRY NEEDS A NEW AND INNOVATIVE APPROACH TO CLINICAL TRIALS ”
Q . HOW CAN THE PROCESS BE SIMPLIFIED ?
» Particularly gaining ground are decentralised trials , where the trial process is moved into the patients ’ home , rather than a traditional trial centre . These are becoming increasingly possible thanks to technologies such as artificial intelligence , machine learning and cloud computing , and it ’ s also sparking a renewed drive for patient centricity across the health sector .
Decentralised clinical trials are far more patient-centric since they build convenience and flexibility into the process . There ’ s no need for travel , nor the pressure to attend medical facilities and the patient is empowered to act - this has the potential to vastly improve compliance and recruitment rates , not to mention opening participation up to a more diverse pool of people .
20 April 2021